Picture of Dogwood Therapeutics logo

DWTX — Dogwood Therapeutics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapValue Trap

Virios Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

* Virios Therapeutics Inc  VIRI.OQ  reported a quarterly
adjusted
loss of 5 cents​​ per share for the quarter ended in June,
higher than the same quarter last year, when the company
reported EPS of -8 cents.  The mean expectation of
three analysts for the quarter was for a loss of 6 cents per
share. Wall Street expected results to range from -7 cents to -5
cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Virios Therapeutics Inc's reported EPS for the quarter was
a
loss of 5 cents​.
    * The company reported a quarterly loss of $1.05 million.
    * Virios Therapeutics Inc shares had fallen by 12.9% this
quarter and lost 67.4% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 58.3%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is  "hold."

Wall Street's median 12-month price target for Virios
Therapeutics Inc is $1.00 
This summary was machine generated from LSEG data August 8 at
03:01 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2024      -0.06          -0.05          Beat
 Mar. 31 2024      -0.04          -0.07          Missed
 Dec. 31 2023      -0.09          -0.06          Beat
 Sep. 30 2023      -0.09          -0.06          Beat

Recent news on Dogwood Therapeutics

See all news